$NFRM announced that it has completed the licensing of GLB333 from Globe Laboratories. NFRM obtained the worldwide exclusive license to the use and marketing of a cytokine that is shown to have profound effects on the management of pain due to trauma, wound, and accidents, as well as autoimmune conditions. http://t.co/6g3n3KI 03/22/11